Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy

BJU International

Volumn 85, Issue 7, 2000, Pages 829-835

  Cooke, P W ^b   James, N D ^a   Ganesan, R ^a   Burton, A ^a   Young, L S ^a   Wallace, D M A ^c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Bcl 2; Bladder cancer; Chemotherapy; Neoadjuvant; Radiotherapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; PROTEIN BCL 2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CYSTECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0034053169     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00612.x     Document Type: Article

References (30)

1. 1 Advanced Bladder Cancer Overview Collaboration: Ghersi D, Stewart LA, Parmar MKB et el. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer - a meta-analysis of individual patient data from randomized clinical trials. Br J Urol 1995; 75: 206-13
2. 2 International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533-40
3. 3 Martinez-Pineiro JA, Martinez-Pineiro L. The role of neoadjuvant chemotherapy for invasive bladder cancer. Br J Urol 1998; 82: 33-42
4. 4 Stein J, Grossfeld G, Ginsberg D et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998; 160: 645-59
5. 5 Hellemans P, van Dam P, Weyler J, van Oosterom A, Buytaeri P, Van Marck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer 1995; 72: 354-60
6. 6 Krajewska M, Krajewska S, Epstein J et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567-76
7. 7 Gallo O, Boddi V, Calzolari A, Simonetti L, Trovatti M, Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996; 2: 261-7
8. 8 Harima Y, Harima K, Shikata N, Oka A, Ohnishi T, Tanaka Y. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 1998; 124: 503-10
9. 9 Apakama I, Robinson M, Walter N et al. Bcl-2 over-expression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer 1996; 74: 1258-62
10. 10 King ED, Matteson J, Jacobs SC, Kyprianou N. Incidence of apoptosis, cell-proliferation and Bcl-2 expression in transitional-cell carcinoma of the bladder - association with tumor progression. J Urol 1996; 155: 316-20
11. 11 Shiina H, Igawa M, Urakami S, Honda S, Shirakawa H, Ishibe T. Immunohistochemical analysis of Bcl-2 expression in transitional cell carcinoma of the bladder. J Clin Pathol 1996; 49: 395-9
12. 12 Ye D, Li H, Qian S, Sun Y, Zheng J, Ma Y. Bcl-2/Bax expression and p53 gene status in human bladder cancer: Relationship to early recurrence with intravesical chemotherapy after resection. J Urol 1998; 160: 2025-9
13. 13 Pollack A, Wu CS, Czerniak B, Zagars GK, Benedict WF, McDonnell TJ. Abnormal Bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer. Clin Cancer Res 1997; 3: 1823-9
14. 14 Kong G, Shin KY, Oh YH et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998; 37: 715-20
15. 15 Lee E, Park I, Lee C. Prognostic markers of intravesical Bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers. Int J Urol 1997; 4: 552-6
16. 16 Cooke PW, James ND, Ganesan R, Wallace DMA, Burton A, Young LS. Bcl-2 expression is not a prognostic marker in bladder cancer. BJU Int 1999; 84: 139
17. 17 Li B, Kanamaru H, Noriki S, Yamaguchi T, Fukuda M, Okada K. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder. Urol Res 1998; 26: 235-41
18. 18 Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson MA. Invasion of the bladder by transitional cell carcinoma. Its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer 1998; 82: 715-23
19. 19 Wallace DMA, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-15
20. 20 Cordell JL, Falini B, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984; 32: 219-29
21. 21 Altman D. Practical Statistics for Medical Research. London: Chapman & Hall 1991
22. 22 Okamura T, Akita H, Kawai N, Tozawa K, Yamada Y, Kohri K. Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers. Urol Res 1998; 26: 161-4
23. 23 Gazzaniga P, Gradilone A, Silvestri I et al. Variable levels of bcl-2, bcl-X and bax mRNA in bladder cancer progression. Oncol Rep 1998; 5: 901-4
24. 24 Clynes M, Daly C, NicAmhlaoibh R et al. Recent developments in drug resistance and apoptosis research. Crit Rev Oncol Haematol 1998; 28: 181-205
25. 25 Eliopoulos AG, Kerr DJ, Herod J et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-28
26. 26 Miyake H, Hanada N, Nakamura H et al Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 16: 933-43
27. 27 Strasser A, Harris AW, Jacks T. DNA damage can induce apoptosis in proliferating lymphoid cells via p53 independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-39
28. 28 Kernohan NM, Cox LS. Regulation of apoptosis by Bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3
29. 29 Qureshi KN, Leyshon Griffiths TR, Robinson MC et al. Radical radiotherapy and muscle-invasive bladder cancer: combined WAF1 and TP53 over-expression predict improved survival. BJU Int 1999; 84: 140
30. 30 Webb A, Cunningham D, Cotter F et al. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997; 349: 1137-41